[Vasopeptidase inhibition. A new mechanism of action for the treatment of hypertension and cardiac insufficiency].
Krankenanstalten Gilead, Medizinische Klinik, Akademisches Lehrkrankenhaus der Westfälischen Wilhelms-Universität Münster, Burgsteig 13, 33617 Bielefeld. kolloch@gilead.de
R
R
Kolloch
E
E
Offers
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D013841:Thiazepines / Q000494:pharmacology* / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002317:Cardiovascular Agents; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat; D015260:Neprilysin